Blood consult: Resistant and progressive essential thrombocythemia

Blood

Volumn 118, Issue 2, 2011, Pages 240-242

  Tibes, Raoul ^a   Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; HYDROXYUREA; JANUS KINASE 2 INHIBITOR; MELPHALAN;

ADD ON THERAPY; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CONSULTATION; DISEASE COURSE; DRUG WITHDRAWAL; HUMAN; LUNG EMBOLISM; MALE; MEDICAL HISTORY; NEUTROPENIA; NIGHT SWEAT; PHYSICAL EXAMINATION; POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS; PRIORITY JOURNAL; SKIN DISCOLORATION; SPLENOMEGALY; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPHERESIS; THROMBOCYTOSIS; WEIGHT REDUCTION;

EID: 79960467729     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-327213     Document Type: Article

References (10)

1. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132-1136.
2. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45. (Pubitemid 41007805)
3. Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007;21(2):277-280. (Pubitemid 46158120)
4. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418-5424.
5. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438. (Pubitemid 351250553)
6. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
7. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
8. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264- 5270.
9. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
10. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/ JAK2 inhibitor, INCB018424, In patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 313.